Abstract
The bone marrow (BM) is a well-recognized source of stem/progenitor cells for cell therapy in cardiovascular diseases (CVDs). Preclinical and clinical studies suggest that endothelial progenitor cells (EPCs) contribute to reparative process of vascular endothelium and participate in angiogenesis. As for all organs and cells across the lifespan, BM and EPCs are negatively impacted by ageing due to microenvironment modifications and EPC progressive dysfunctions. The encouraging results in terms of neovascularization observed in young animals after EPC administration were mitigated in aged patients treated for ischemic CVDs. The limited efficacy of EPC-based therapy in clinical setting might be ascribed at least partly to ageing. In this review, we comprehensively discussed the age-related changes of BM and EPCs and their implication for cardiovascular cell-therapies. Finally, we examined alternative approaches under investigation to enhance EPC potency.
| Original language | English |
|---|---|
| Pages (from-to) | 4-13 |
| Number of pages | 10 |
| Journal | Mechanisms of Ageing and Development |
| Volume | 159 |
| DOIs | |
| Publication status | Published - Oct 2016 |
Fingerprint
Keywords
- Review
- Journal Article
Cite this
BM ageing : Implication for cell therapy with EPCs. / Rurali, Erica; Bassetti, Beatrice; Perrucci, Gianluca Lorenzo; Zanobini, Marco; Malafronte, Cristina; Achilli, Felice; Gambini, Elisa.
In: Mechanisms of Ageing and Development, Vol. 159, 10.2016, p. 4-13.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - BM ageing
T2 - Implication for cell therapy with EPCs
AU - Rurali, Erica
AU - Bassetti, Beatrice
AU - Perrucci, Gianluca Lorenzo
AU - Zanobini, Marco
AU - Malafronte, Cristina
AU - Achilli, Felice
AU - Gambini, Elisa
N1 - Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
PY - 2016/10
Y1 - 2016/10
N2 - The bone marrow (BM) is a well-recognized source of stem/progenitor cells for cell therapy in cardiovascular diseases (CVDs). Preclinical and clinical studies suggest that endothelial progenitor cells (EPCs) contribute to reparative process of vascular endothelium and participate in angiogenesis. As for all organs and cells across the lifespan, BM and EPCs are negatively impacted by ageing due to microenvironment modifications and EPC progressive dysfunctions. The encouraging results in terms of neovascularization observed in young animals after EPC administration were mitigated in aged patients treated for ischemic CVDs. The limited efficacy of EPC-based therapy in clinical setting might be ascribed at least partly to ageing. In this review, we comprehensively discussed the age-related changes of BM and EPCs and their implication for cardiovascular cell-therapies. Finally, we examined alternative approaches under investigation to enhance EPC potency.
AB - The bone marrow (BM) is a well-recognized source of stem/progenitor cells for cell therapy in cardiovascular diseases (CVDs). Preclinical and clinical studies suggest that endothelial progenitor cells (EPCs) contribute to reparative process of vascular endothelium and participate in angiogenesis. As for all organs and cells across the lifespan, BM and EPCs are negatively impacted by ageing due to microenvironment modifications and EPC progressive dysfunctions. The encouraging results in terms of neovascularization observed in young animals after EPC administration were mitigated in aged patients treated for ischemic CVDs. The limited efficacy of EPC-based therapy in clinical setting might be ascribed at least partly to ageing. In this review, we comprehensively discussed the age-related changes of BM and EPCs and their implication for cardiovascular cell-therapies. Finally, we examined alternative approaches under investigation to enhance EPC potency.
KW - Review
KW - Journal Article
U2 - 10.1016/j.mad.2016.04.002
DO - 10.1016/j.mad.2016.04.002
M3 - Article
C2 - 27045606
VL - 159
SP - 4
EP - 13
JO - Mechanisms of Ageing and Development
JF - Mechanisms of Ageing and Development
SN - 0047-6374
ER -